Chair: Peter Greenleaf, Chief Executive Officer, Sucampo Pharmaceuticals, Inc.
Staff Contact: Frederick Bittenbender, Executive Vice President, Public Affairs, fbittenbender(at)bio.org
Description: The committee provides strategic oversight of membership-related issues, offering guidance and recommendations on various activities, including but not limited to, dues structure (potential dues increases and/or restructuring); the development of a strategic membership plan; and the enhancement of member services and related resources.
Daniel Tasse, Chairman & CEO, Ikaria, Inc.
David Pyott, President & CEO, Allergan, Inc.
Hervé Hoppenot, President & CEO, Incyte Corporation
John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
John Orwin, Chief Executive Officer, Relypsa, Inc.
Kristine Peterson, Chief Executive Officer, Valeritas, Inc.
Mark Skaletsky, Chairman & CEO, Fenway Pharmaceuticals, Inc.
Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc.
Ron Cohen, President & CEO, Acorda Therapeutics, Inc.
Ronald Stotish, Chief Executive Officer, Aqua Bounty Technologies, Inc.
Robert Kiss, Portfolio Manager, JP Morgan Asset Management
Steven Mento, President & CEO, Co-Founder and Chairman, Conatus Pharmaceuticals, Inc.
Timothy Rodell, President & CEO, GlobeImmune, Inc.
Timothy Walbert, Chairman, President & CEO, Horizon Pharma, Inc.